The Swedish pharmaceutical company Moberg Derma today announces that it is strengthening its organization through the recruitment of Martin Ingman as Sales & Marketing Director.

Moberg Derma AB reports today positive results from a phase III clinical study for K101 against nail fungus (onychomycosis). In the study, almost 500 patients were treated during six months with K101 or a placebo. The results showed that significantly more patients receiving K101 were cured of their fungal infection (p=0.001). The patients' subjective evaluation of the treatment effect revealed distinct benefits from treatment with K101 (p<0.001). Highly promising results were also observed for patients with severely infected nails.

Moberg Derma is today reporting promising results from a phase III study for K301 against seborrheic dermatitis. The study showed that K301 was significantly superior to placebo for several key efficacy endpoints, including a marked effect on the degree of scaling after two and four weeks of treatment. Both the patient’s and the doctor’s global assessment of the treatment efficacy were clearly in favor of K301. No serious adverse events were reported and no patient discontinued treatment due to an adverse event.

The Swedish pharmaceutical company Moberg Derma, which focuses on skin diseases, has completed a new issue generating SEK 40 million (EUR 4,3 million). The issue has been subscribed by a new private investor and the current principal owner, the Baltic Sea Foundation (Östersjöstiftelsen). Including this new issue, the company has raised SEK 73 million (EUR 8 million) since its founding in March 2006.

The Swedish pharmaceutical company Moberg Derma, which focuses on skin diseases, has finalized patient recruitment for a clinical phase III trial of the K101 product candidate to treat nail fungus (onychomycosis). The recruitment of patients has been finalized faster than expected and the study will include over 500 patients at 40 clinics in Sweden and Poland. Results from the trial are expected in the second half of 2008.

The Swedish pharmaceutical company Moberg Derma, which focuses on skin diseases, has started recruiting patients for a clinical phase III trial of the K301 product candidate to treat seborrheic dermatitis of the scalp. The company plans to include 180 patients in the study at around 20 clinics in Sweden. The results from the trial are expected in the second half of 2008.